Cite
HARVARD Citation
Besse, B. et al. (n.d.). Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). European journal of cancer. pp. S75-S76. [Online].